TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean MB plasma area under the substrate concentration‐time curve (AUC 0‐infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma drug concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half‐life (t1/2beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year TRM rate
Endpoint domain: Mortality/survival
Primary endpoint: Cataract incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Lesion detection in the abdomen, liver, and pelvis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance time of 131I‐Mu‐9 immunoglobulin G and 131I‐F(ab')2 from the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average tumor dose for 131I‐Mu‐9 immunoglobulin G and 131I‐F(ab')2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid decrease in total immunoglobulin G (IgG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rapid and long-lasting disease improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term morbidity and mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: 1-year morbidity and mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: FitzGibbon A graft patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Killing of vaccine serogroup B and C strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum bactericidal activity (4-fold increase in titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cross-reactive immunogenicity against heterologous serogroup B strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Procollagen type I N-terminal propeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sperm density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cutaneous hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: contact angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: LGA birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: HIV/AIDS knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epithelial healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alpha1 (heart rate variability parameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV-1 DNA levels in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increasing psychosocial functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rehospitalisation rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: TMD pain risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean characteristic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of major airway events
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of airway events of any severity
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of laryngospasm and coughing of any severity
Endpoint domain: Adverse events/effects
Primary endpoint: social competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional self-regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetically acceptable repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow reserve utilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for a transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of responding patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strategic memory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: vigor
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Child Turcotte Pugh score (CTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at day 15
Endpoint domain: Mortality/survival
Primary endpoint: HIV RNA levels <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall stone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for additional stone management procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24-hour mean SBP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standard deviation of SRTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between first and second SRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first twitch at 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with TOF ratio <80%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miR-181a-5p expression for TCMAR risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miR-155-5p expression for SCR risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak serum concentration (Cmax) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratio of simvastatin acid to simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8‐OH‐dG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-of-life indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: N2 latency shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Contact heat evoked pain ratings increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in long-term counseling
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decline in the number of contacts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global quality of Doppler investigations
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of clinically useful signal enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ischemia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: extracorporeal circulation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transient Ischemic Attacks (TIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrent Ischaemic Strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of trials clearly identified as cluster randomized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional pain after laparoscopic cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate for the first breast feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, myocardial infarction, or unstable angina
Endpoint domain: Mortality/survival
Primary endpoint: Increase in MVPA minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater peer support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Serum HMGB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful TWOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal anti-HB antibody levels at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increases in V˙O2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreases in sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED attitudes and behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ED onset rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coagulation variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum concentrations of IL‐6, IL‐8 and TNF‐a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: engagement and behavioural changes linked to personal values
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Range of motion at the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ejection Fraction (EF) at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean duration of incapacity to work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency and intensity of anginal attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ergometric exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of ST-depression in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfused boundary region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Partial responses (PRs) in patients with trastuzumab-resistant breast cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable disease in patients receiving lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of drug-related adverse events (diarrhea and rash)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean serum VitD levels after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: C-reactive protein serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI3 <2 episodes per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) values at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) values during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative consumption of fentanyl and morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Experience of sexual victimization
Endpoint domain: Adverse events/effects
Primary endpoint: OSDI (Ocular Surface Disease Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HLA-DR-positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bronchial and nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchodilator use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: daily cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of drunkenness in the past 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHD incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood glycerol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: worsening retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Increase in T‐reg cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of CD8+CD28‐ T‐cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of IFN‐γ/IL‐4 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lp(a) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microembolic signals (MES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in bronchoconstrictor response to AMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Back pain disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rate of decline in CCr (dCCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum 25‐hydroxycholecalciferol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization as a result of HF
Endpoint domain: Mortality/survival
Primary endpoint: fear of movement/(re)injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Good outcome at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transfer to another methadone program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: DQI-I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intent to undergo screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adherence determination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: screening participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Differential expression of miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of full jaw relaxation at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Easy insertion of LMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bowel function improvement (frequency and ease of defecation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal weight increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Short-chain fatty acid production increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: physician global assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong‐Baker FACES pain rating scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of patients using rescue analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating nucleosome levels
Endpoint domain: Mortality/survival
Primary endpoint: urinary albumin-to-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Serum interleukin 10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MDI (Mental Development Index)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Event-free survival rates at 8 years
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to first stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of stools in 24-hour follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: functional hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in family caregivers' preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvements in family caregivers' competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: more favourable levels of psychological wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elevated levels of IGF‐I and IGF binding protein‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of functional limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in patients with elevated lactate
Endpoint domain: Mortality/survival
Primary endpoint: Childhood overweight or obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma γ‐glutamyltransferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma hs‐CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma LDL/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health benefits of ILR as a screening tool for AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cost-effectiveness of ILR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean improvement in physical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of feelings of SNDH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of tingling feeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial oxygenation index (p(a)O(2)/F(I)O(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oxygenation responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary shunt fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alveolar-arterial oxygen tension difference [P(a-a)o2]/Pao2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of death, myocardial infarction, or recurrent angina
Endpoint domain: Mortality/survival
Primary endpoint: Need for revascularization procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in blood triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elevation in cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Elevation in DHEA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Return visit to the ED or hospitalization at 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention